Next-gen sequencing tech from GenapSys nets $37M round

Genomic sequencing specialist GenapSys picked up $37 million in Series B financing to help develop and commercialize its diagnostic system for genetic diseases, cancer and microbes. The California company's GENIUS 110--Gene Electronic Nano-Integrated Ultra-Sensitive--is designed to be inexpensive and easy to use, according to the company, combining advanced fluidics and analytics for DNA and RNA sequencing. The cash infusion follows a recent trend of sizable investments in next-gen sequencing, including $15 million for NextCODE Health and $50 million for Enzymatics, both Massachusetts outfits. "I believe now is the decade of genomics," GenapSys CEO Hesaam Esfandyarpour said in a statement. More from FierceDiagnostics

Suggested Articles

BD will begin working with Babson Diagnostics to help bring its lab-quality device for collecting blood from capillaries into retail pharmacies.

The former CEO of the molecular testing company Foundation Medicine, Troy Cox, has been named chairman of the Swiss big data firm Sophia Genetics.

Researchers at MIT used a machine-learning algorithm to uncover the potent antibiotic properties hiding within an old small-molecule candidate.